Illumina Launches $100M Share Repurchase Program | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina announced today that its board of directors has authorized a $100 million share repurchase program.

The firm may acquire on a discretionary basis up to $100 million worth of its outstanding common shares on the open market or through privately negotiated transactions. Its previous $100 million share repurchase program, which was authorized in July 2010, was completed this week, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.